Biopharma Dealmaking Quarterly Statistics, Q2 2014
A look at financing, M&A, and alliance activity April–June 2014
Executive Summary
Biopharma financing totaled $7.2 billion, a 36% decrease from Q1; 36 completed M&As had a combined potential value reaching $116 billion, more than three-and-a-half times the previous quarter; 84 biopharma alliances, together totaling $7.7 billion in potential pre-commercialization value, showed a significant jump from Q1’s $1.9 billion aggregate.
You may also be interested in...
A Banner Year For Pharma: M&A Tops 2009 Merger Mania
Fourteen deals have been signed so far in 2014 with an up-front value of $1 billion or more. The standout year for pharma M&A is already more valuable than 2009, the year Pfizer bought Wyeth and Merck acquired Schering-Plough.
Hikma To Buy Bedford, Transfer Manufacturing For U.S. Generics Injectables
Ben Venue’s shuttered Ohio plant is also slated to be part of the transaction, but Hikma’s initial focus is on moving acquired assets into its production facilities, even though the Jordan-based firm expects only limited revenue from them over the next two years.
Aastrom Adds Revenues Through $6.5M Regen Med Buy From Sanofi
The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.